Research



Technology Focus
 
Innovative peptide-based formulations for therapeutic nucleic acid delivery to Human HER2+ cancers

Background

Efficient gene delivery facilitated by non-viral vectors is relatively safe. Novel peptide-based carriers enhance nucleic acid import into all types of cells. Cell-specific targeting is vital to enhance safety and efficacy of therapeutic nucleic acids. Recombinant peptide conjugates encompassing a novel class of biomolecules with given targets have been developed through multiple efforts for molecular diagnostics and imaging. At CSIR-CCMB, we designed novel peptide-based chimeras for cell-specific targeting to efficiently import therapeutic DNA and siRNA into cells. 

Utility

Modular recombinant peptides elicit their function by targeting HER2+ cancer cells efficiently. The devised peptide chimeras and formulations developed at CSIR-CCMB are suitable carriers of therapeutic nucleic acids. Formulations are stable, safe, mediate cell-specific DNA import and efficient distribution of nucleic acids in tumors. The strategy can be additionally used to deliver gene silencers for validation.

Product development

CSIR-CCMB is interested in discussions on the possibility of further development through Industry collaboration to make product formulations. There is great scope for new strategies for cancer therapy.

Contact Person:

Director

Centre for Cellular and Molecular Biology 

Uppal Road, Hyderabad - 500 007 

Andhra Pradesh, India

E-mail: director@ccmb.res.in

Phone: 91-40-27160789

Fax: 91-40-27160591